REG - GSK PLC - Transaction in Own Shares

GSKAnnouncement

Mon 15:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260518:nRSR7738Ea&default-theme=true

RNS Number : 7738E  GSK PLC  18 May 2026

Transaction in own shares

 

GSK plc (the "Company") announces today acting through Citigroup Global
Markets Limited (the "Broker"), it has purchased the following number of the
Company's ordinary shares of 31¼ pence each.

 

 Date of purchase  Aggregate number of ordinary shares of 31 ¼ pence each purchased   Lowest price paid per share (GBp)  Highest price paid per share (GBp)  Volume weighted average price paid per share (GBp)
 11 May 2026       323,368                                                            1,841.00                           1,869.00                            1,855.48
 12 May 2026       342,412                                                            1,827.00                           1,887.50                            1,868.04
 13 May 2026       333,903                                                            1,865.50                           1,897.00                            1,882.24
 14 May 2026       334,877                                                            1,869.00                           1,890.00                            1,879.23
 15 May 2026       337,291                                                            1,855.50                           1,899.50                            1,874.08

 

 

The purchased shares will be held as Treasury shares.

 

Such share purchases form part of the Company's existing buyback programme and
was effected pursuant to the non-discretionary agreement entered into with the
Broker on 8 May 2026, as announced on 11 May 2026.  Since 11 May 2026 the
Company has purchased 1,671,851 ordinary shares.

 

Following the above purchases, the Company will hold 263,050,137 ordinary
shares in treasury and have 4,053,167,539 ordinary shares in issue (excluding
Treasury shares).

 

Following the above purchases, the total number of voting rights in the
Company will be 4,053,167,539. This figure may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure Guidance and
Transparency Rules.

 

The Company confirms that, in accordance with DTR 5.5.1R, following the above
purchases the percentage of voting rights attributable to the ordinary shares
held in treasury is 6.49 per cent.

 

In accordance with Article 5(1)(b) of the Market Abuse Regulation (EU) No
596/2014, as it forms part of domestic law by virtue of the European Union
(Withdrawal) Act 2018, as amended, a full breakdown of the individual
purchases of ordinary shares made by the Broker on the London Stock Exchange
and the CBOE Europe Limited recognised investment exchange (through its order
books having market identification codes CHIX or BATE) is set out in the
Schedule to this announcement, available via the link below:

 

http://www.rns-pdf.londonstockexchange.com/rns/7738E_1-2026-5-18.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/7738E_1-2026-5-18.pdf)

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(https://www.gsk.com) .

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)

 Investor Relations:  Constantin Fest    +44 (0) 7831 826525   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Sam Piper          +44 (0) 7824 525779   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 3126       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and
GSK's Q1 Results for 2026.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSAKFBQNBKDAPD



            Copyright 2019 Regulatory News Service, all rights reserved